Effective inhibition of dengue virus replication using 3'UTR-targeted Vivo-Morpholinos.

ABSTRACT:

Introduction

Due to the impact of antibody-dependent enhancement and viral variation, effective vaccines or antiviral therapies remain lacking for the dengue virus (DENV). Nucleic acid drugs, particularly Vivo-Morpholinos (MOs), have emerged as a promising avenue for antiviral treatment due to their programmability and precise targeting, as well as their safety and stability.

Method

In this study, we designed and developed 10 morpho-modified (octa-guanidine dendrimer) vivo-MO molecules that target each coding gene of DENV. Subsequently, we assessed the inhibitory impact of vivo-MOs on dengue viral RNA load utilizing qRT-PCR. Furthermore, we examined the inhibitory effect on the live virus through a plaque assay and the TCID50 assay.

Results

We found that the vivo-3'UT

SUBMITTER: Niu M 

PROVIDER: S-EPMC11638040 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature